Antibiotic treatment for the sexual partners of women with bacterial vaginosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 10, 2016, Pages

  Amaya Guio, Jairo ^a   Viveros Carreño, David Andres ^a   Sierra Barrios, Eloisa Mercedes ^a   Martinez Velasquez, Mercy Yolima ^b   Grillo Ardila, Carlos F ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Clinica Universitaria Colombia   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROIMIDAZOLE; ANTIBIOTIC AGENT; LINCOSAMIDE; METRONIDAZOLE; TINIDAZOLE; 5-NITROINDAZOLE; ANTIINFECTIVE AGENT; CLINDAMYCIN; INDAZOLE DERIVATIVE;

ANTIBIOTIC THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SEXUALITY; STUDY DESIGN; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); THERAPY EFFECT; TREATMENT DURATION; VAGINITIS; ADOLESCENT; ADULT; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; SECONDARY PREVENTION; TIME FACTOR; VAGINOSIS, BACTERIAL;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; FEMALE; HUMANS; INDAZOLES; LINCOSAMIDES; MALE; METRONIDAZOLE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION; SEXUAL PARTNERS; TIME FACTORS; TINIDAZOLE; VAGINOSIS, BACTERIAL;

EID: 84989227669     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011701.pub2     Document Type: Review

References (69)

1. Colli E, Landoni M, Parazzini F. Treatment of male partners and recurrence of bacterial vaginosis: a randomised trial. Genitourinary Medicine 1997;73(4):267-70.
2. Heikkinen J, Vuopala S. Anaerobic vaginosis: treatment with tinidazole vaginal tablets. Gynecologic and Obstetric Investigation 1989;28(2):98-100.
3. Mengel MB, Berg AO, Weaver CH, Herman DJ, Herman SJ, Hughes VL, et al. The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis. Journal of Family Practice 1989;28(2):163-71.
4. Moi H, Erkkola R, Jerve F, Nelleman G, Bymose B, Alaksen K, et al. Should male consorts of women with bacterial vaginosis be treated?. Genitourinary Medicine 1989;652(4):263-8.
5. Swedberg J, Steiner JF, Deiss F, Steiner S, Driggers DA. Comparison of single-dose vs one-week course of metronidazole for symptomatic bacterial vaginosis. JAMA 1985;254(8):1046-9.
6. Vejtorp M, Bollerup AC, Vejtorp L, Fanøe E, Nathan E, Reiter A, et al. Bacterial vaginosis: a double-blind randomized trial of the effect of treatment of the sexual partner. British Journal of Obstetrics and Gynaecology 1988;95(9):920-6.
7. Vutyavanich T, Pongsuthirak P, Vannareumol P, Ruangsri RA, Luangsook P. A randomized double-blind trial of tinidazole treatment of the sexual partners of females with bacterial vaginosis. Obstetrics and Gynecology 1993;82(4 Pt 1):550-4.
8. Brenner WE, Dingfelder JR. Metronidazole-containing vaginal sponges for the treatment of bacterial vaginosis. Advances in Contraception 1986;2(4):363-9.
9. Bukusi E, Thomas KK, Nguti R, Cohen CR, Weiss N, Coombs RW, et al. Topical penile microbicide use by men to prevent recurrent bacterial vaginosis in sex partners: a randomized clinical trial. Sexually Transmitted Diseases 2011;38(6):483-9.
10. Eschenbach DA, Critchlow CW, Watkins H, Smith K, Spiegel CA, Chen KC, et al. A dose-duration study of metronidazole for the treatment of nonspecific vaginosis. Scandinavian Journal of Infectious Diseases. Supplementum 1983;40:73-80.
11. Giraldo PC, Rodrigues HM, Melo AG, do Amaral RL, Passos MRL, Eleutećrio J, et al. Vulvovaginitis and the treatment of asymptomatic partners: a systematic review and meta-analysis. Jornal Brasileiro de Doenças Sexualmente Transmissíveis 2013;25(1):36-40.
12. Hagström B, Lindstedt J. Comparison of two different regimens of metronidazole in the treatment of non-specific vaginitis. Scandinavian Journal of Infectious Diseases. Supplementum 1983;40:95-6.
13. Høvik P. Nonspecific vaginitis in an outpatient clinic. Comparison of three dosage regimens of metronidazole. Scandinavian Journal of Infectious Diseases. Supplementum 1983;40:107-10.
14. Jerve F, Berdal TB, Bohman P, Smith CC, Evjen OK, Gjønnaess H, et al. Metronidazole in the treatment of non-specific vaginitis (NSV). British Journal of Venereal Diseases 1984;60(3):171-4.
15. Koumans EH, Markowitz LE, Hogan V, CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clinical Infectious Diseases 2002;35(Suppl 2):S152-72.
16. Larsson PG, Brandsborg E, Forsum U, Pendharkar S, Andersen KK, Nasic S, et al. Extended antimicrobial treatment of bacterial vaginosis combined with human lactobacilli to find the best treatment and minimize the risk of relapses. BMC Infectious Diseases 2011;11:223. [DOI: 10.1186/1471-2334-11-223]
17. Mehta SD. Systematic review of randomised trials of treatment of male sexual partners for improved bacteria vaginosis outcomes in women. Sexually Transmitted Diseases 2012;39(10):822-30.
18. Potter J. Should sexual partners of women with bacterial vaginosis receive treatment?. British Journal of General Practice 1999;49(448):913-8.
19. Sharma JB, Mittal S, Raina U, Chanana C. Comparative efficacy of two regimens in syndromic management of lower genital infections. Archives of Gynecology and Obstetrics 2006;273(4):232-5.
20. NCT02209519 Randomized controlled trial of treatment of male partners of women With BV. clinicaltrials.gov/ct2/show/NCT02209519 (first received 4 August 2014).
21. Amit A, Rawat DS, Rawat MSM. 5-Nitroimidazole derivatives: a scope of modification for medicinal chemists. Research Journal of Chemical Science 2013;3(7):104-13.
22. Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, et al. The burden of bacterial vaginosis: women's experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PLoS One 2013;8(9):e74378.
23. Bouazza N, Pestre V, Jullien V, Curis E, Urien S, Salmon D, et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. British Journal of Clinical Pharmacology 2012;74(6):971-7.
24. Bradshaw CS, Morton AN, Garland SM, Morris MB, Moss LM, Fairley CK. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstetrics and Gynecology 2005;106(1):105-14. [PUBMED: 15994624]
25. Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. Journal of Infectious Diseases 2006;193(11):1478-86. [PUBMED: 16652274]
26. Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD000262.pub4]
27. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. Journal of Clinical Investigation 2011;121(12):4610-7.
28. Brunton LL, Chabner BA, Knollman BC, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th Edition. New York (NY): McGraw-Hill Companies Inc., 2011.
29. Chavez N, Molina H, Sánchez J, Gelaye B, Sánchez SE. Douches and other risks of bacterial vaginosis [Duchas vaginales y otros riesgos de vaginosis bacteriana]. Revista Peruana de Medicina Experimental y Salud Pública 2009;26(3):299-306. [PUBMED: 21132048]
30. Cook RL, Redondo-Lopez V, Schmitt C, Meriwether C, Sobel JD. Clinical, microbiological and biochemical factors in recurrent bacterial vaginosis. Journal of Clinical Microbiology 1992;30(4):870-7.
31. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Medical Journal of Australia 1993;158(9):600-2.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
33. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clinical Infectious Diseases 2008;47(11):1426-35. [PUBMED: 18947329]
34. Fethers KA, Fairley CK, Morton A, Hocking JS, Hopkins C, Kennedy LJ, et al. Early sexual experiences and risk factors for bacterial vaginosis. Journal of Infectious Diseases 2009;200(11):1662-70. [PUBMED: 19863439]
35. Flaherty JF Jr, Gatti G, White J, Bubp J, Borin M, Gambertoglio JG. Protein binding of clindamycin in sera of patients with AIDS. Antimicrobial Agents and Chemotherapy 1996;40(5):1134-8.
36. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrobial Agents and Chemotherapy 1993;37(5):1137-43.
37. Gillet E, Meys JF, Verstraelen H, Verhelst R, De Sutter P, Temmerman M, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLoS One 2012;7(10):e45201.
38. Goldenberg RL, Culhane JF, Johnson DC. Maternal infection and adverse fetal and neonatal outcomes. Clinics in Perinatology 2005;32(3):523-59.
39. GRADEpro. [Computer program on www.gradepro.org]. Version [July, 2016]. McMaster University, 2014.
40. Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. Journal of Infectious Diseases 1977;135 Suppl:S104-10.
41. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
42. Higgins JPT, Green S, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
43. Josefsson K, Bergan T, Magni L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. British Journal of Clinical Pharmacology 1982;13(5):685-91.
44. Kenyon C, Colebunders R, Crucitti T. The global epidemiology of bacterial vaginosis: a systematic review. American Journal of Obstetrics and Gynecology 2013;209(6):505-23.
45. Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clinical Pharmacokinetics 1999;36(5):353-73.
46. Madhivanan P, Barreto GA, Revawala A, Anderson C, McKinney S, Pierre-Victor D. Where are we with partner treatment in bacterial vaginosis? A critical appraisal of the latest systematic review. Sexually Transmitted Diseases 2013;40(6):518.
47. Mandar R. Microbiota of male genital tract: impact on the health of man and his partner. Pharmacological Research 2013;69(1):32-41. [PUBMED: 23142212]
48. Marrazzo J, Coffey P, Bingham A. Sexual practices, risk perception and knowledge of sexually transmitted disease risk among lesbian and bisexual women. Perspectives on Sexual and Reproductive Health 2005;37(1):6-12. [PUBMED: 15888397]
49. Marrazzo JM. Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused?. Anaerobe 2011;17(4):186-90.
50. Mehta SD. Response to Madhivanan et al. Sexually Transmitted Diseases 2013;40(6):518-9.
51. Ministerio de Salud y Protección Social - Colciencias. Clinical Practice Guideline for the syndromic approach to the diagnosis and treatment of patients with sexually transmitted infections and other infections of the genital tract. [Guića de praćctica clićnica para el manejo sindroćmico de los pacientes con infecciones de transmisioćn sexual y otras infecciones del tracto genital]. http://gpc.minsalud.gov.co/gpc_sites/repositorio/conv_500/GPC_its/gpc_its.aspx April 2013. Accessed 23/07/2015.
52. Mirmonsef P, Krass L, Landay A, Spear GT. The role of bacterial vaginosis and trichomonas in HIV transmission across the female genital tract. Current HIV Research 2012;10(3):202-10.
53. Morris MC, Rogers PA, Kinghorn GR. Is bacterial vaginosis a sexually transmitted infection?. Sexually Transmitted Infections 2001;77(1):63-8. [PUBMED: 11158694]
54. Mylonas I, Bergauer F. Diagnosis of vaginal discharge by wet mount microscopy: a simple and underrated method. Obstetrical & Gynecological Survey 2011;66(6):359-68.
55. Nelson DE, Dong Q, Van der Pol B, Toh E, Fan B, Katz BP, et al. Bacterial communities of the coronal sulcus and distal urethra of adolescent males. PLoS One 2012;7(5):e36298. [PUBMED: 22606251]
56. Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006055.pub2]
57. Oleen-Burkey MA, Hillier SL. Pregnancy complications associated with bacterial vaginosis and their estimated costs. Infectious Diseases in Obstetrics and Gynecology 1995;3(4):149-57.
58. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
59. Sangkomkamhang US, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD006178.pub3]
60. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sexually Transmitted Infections 2004;80(1):58-62.
61. Taylor BD, Darville T, Haggerty CL. Does bacterial vaginosis cause pelvic inflammatory disease?. Sexually Transmitted Diseases 2013;40(2):117-22.
62. Trevor AJ, Katzung BG, Kruidering-Hall M, Masters SB. Katzung & Trevor's Pharmacology Examination and Board Review. 10th Edition. New York (NY): McGraw-Hill Companies Inc., 2012.
63. van Schalkwyk J, Yudin MH, Infectious Disease Committee. Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. Journal of Obstetrics and Gynaecological Canada 2015;37(3):266-76.
64. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015;64(RR-03):1-137.
65. Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metabolism and Disposition 2003;31(7):878-87.
66. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, et al. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metabolism and Disposition 2008;36(8):1689-97.
67. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Medical Clinics of North America 2011;95(4):761-91.
68. Ángel-Müller E, Rodríguez A, Núñez-Forero LM, Moyano LF, González P, Osorio E, et al. The prevalence of and factors associated with C. trachomatis, N. gonorrheae, T. vaginalis, C. albicans infection, syphilis, HIV and bacterial vaginosis in females suffering lower genital tract infection symptoms in three healthcare attention sites in Bogotá, Colombia, 2010. Revista Colombiana de Obstetricia y Ginecología 2012;63(1):25-35.
69. Amaya-Guio J, Martinez-Velasquez MY, Viveros-Carrenco DA, Sierra-Barrios EM, Grillo-Ardila CF. Antibiotic treatment for the sexual partners of women with bacterial vaginosis. Cochrane Database of Systematic Reviews 2015, Issue 5. [DOI: 10.1002/14651858.CD011701]